Metformin — Safety, Research, Risks & Legal Status

Not medical advice. Metformin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Glucophage, biguanide, antidiabetic
Category	GLP-1 / Metabolic
fda_approval_year	1995
global_prescriptions_billions	True
half_life_hours	4.0
ampk_activator	True
US legal status	FDA-approved prescription drug for type 2 diabetes since 1995. Extensively used off-label for metabolic health and longevity. Rx-only; gray-market versions are not the approved pharmaceutical product.

What is Metformin?

A biguanide antidiabetic drug that reduces hepatic glucose production and improves insulin sensitivity via AMPK and mitochondrial mechanisms. One of the most widely used diabetes drugs globally and increasingly explored for longevity in preclinical and observational studies.

How it works

Metformin activates AMPK (AMP-activated protein kinase) which acts as cellular energy sensor. AMPK inhibits mTORC1 (opposite of rapamycin) and activates autophagy. Also reduces hepatic gluconeogenesis and improves mitochondrial function via complex I inhibition.

Background & history

Metformin derived from guanidine (plant compound). Used in Europe since 1950s; FDA-approved USA 1995. Billions of doses used globally. Recently explored for longevity via AMPK mechanism; TAME trial (NIH) initiated 2018.

What the research says

Extensive clinical trials show A1c reduction and modest weight loss in type 2 diabetes. Large observational studies (e.g., Diabetes Prevention Program) show reduced progression to diabetes. Off-label longevity use is based on epidemiological associations and preclinical AMPK activation; randomized human longevity trials are ongoing (e.g., TAME trial).

Reported effects

Reported A1c reduction and improved glucose control in diabetes
Reported modest weight loss (1-3 kg) in clinical trials
Studied for AMPK activation and mitochondrial effects
Observational studies suggest reduced cancer and cardiovascular risk
Possible improved endothelial function and vascular health
Proposed anti-inflammatory effects in metabolic disease

Dosing & administration (informational)

Diabetes dosing: 500-2000 mg daily (IR) or 1000-2000 mg (ER). Off-label longevity use: typically 500-1000 mg daily. TAME trial uses 750 mg daily. No established off-label longevity dose; evidence is limited.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

GI side effects common: nausea, diarrhea, abdominal discomfort (often transient)
Risk of lactic acidosis if renal function impaired (rare but serious); contraindicated in eGFR less than 30 mL/min
B12 malabsorption with long-term use; monitor B12 levels annually
Off-label longevity dosing safety not established (standard diabetes dosing approximately 2000 mg/day)
Long-term safety beyond diabetes indication unknown
Possible dysgeusia (altered taste) and metallic taste reported

Drug & supplement interactions

Contrast agents: lactic acidosis risk if renal function impaired
Diuretics and ACE inhibitors: reduced renal clearance of metformin
Alcohol: lactic acidosis risk, especially binge drinking
Carbonic anhydrase inhibitors (topiramate, acetazolamide): acidosis risk
Other glucose-lowering agents: additive hypoglycemia risk

Who should avoid it

eGFR less than 30 mL/min (absolute contraindication)
Acute illness, sepsis, or surgery with potential hypoxia
Heavy alcohol use or binge drinking
Pregnancy (relative caution; used in gestational diabetes)
Type 1 diabetes or diabetic ketoacidosis

How it is commonly combined

Metformin stacks with other AMPK activators (thiazolidinediones, exercise, fasting) and metabolic modulators (NAD+ precursors) but combinations are understudied; monitor glucose closely with multiple agents.

Legal & regulatory. FDA-approved prescription drug for type 2 diabetes since 1995. Extensively used off-label for metabolic health and longevity. Rx-only; gray-market versions are not the approved pharmaceutical product.

Quality & harm reduction

P
r
e
s
c
r
i
p
t
i
o
n
p
h
a
r
m
a
c
e
u
t
i
c
a
l
;
v
e
r
i
f
y
f
r
o
m
l
i
c
e
n
s
e
d
p
h
a
r
m
a
c
y
.
G
e
n
e
r
i
c
m
e
t
f
o
r
m
i
n
i
s
w
i
d
e
l
y
a
v
a
i
l
a
b
l
e
a
n
d
i
n
e
x
p
e
n
s
i
v
e
;
q
u
a
l
i
t
y
i
s
s
t
a
n
d
a
r
d
i
z
e
d
.
E
x
t
e
n
d
e
d
-
r
e
l
e
a
s
e
(
E
R
)
a
n
d
i
m
m
e
d
i
a
t
e
-
r
e
l
e
a
s
e
(
I
R
)
f
o
r
m
u
l
a
t
i
o
n
s
d
i
f
f
e
r
;
c
l
a
r
i
f
y
f
o
r
m
.
G
r
a
y
-
m
a
r
k
e
t
o
r
n
o
n
-
p
r
e
s
c
r
i
b
e
d
s
o
u
r
c
i
n
g
c
a
r
r
i
e
s
r
i
s
k
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is metformin approved for longevity?

Metformin is approved for type 2 diabetes. Off-label longevity use is based on epidemiological associations; randomized longevity trials (TAME) are ongoing. Efficacy for longevity is not established.

What is the TAME trial?

TAME (Targeting Aging with Metformin) is an ongoing NIH-sponsored trial testing metformin in non-diabetic healthy older adults to assess effects on aging and disease. Results expected 2028-2029.

Does metformin cause lactic acidosis?

Lactic acidosis is rare (1 per 1000 patient-years) and almost always occurs with renal impairment. Contraindicated if eGFR less than 30 mL/min. Renal function monitoring is standard.

What is the evidence for metformin and longevity?

Observational studies and preclinical AMPK activation are promising. No human lifespan trials published. Evidence is indirect; direct longevity benefit is unproven.

Should I take metformin for longevity?

Evidence is insufficient for off-label recommendation. TAME trial results expected 2028-2029. Discuss with physician; not standard of care for non-diabetics currently.

References & further reading

Extensive diabetes trial data and FDA prescribing information
Diabetes Prevention Program large observational registry
TAME trial (NIH Targeting Aging with Metformin) ongoing data
AMPK and autophagy mechanism reviews in aging literature